236 related articles for article (PubMed ID: 19074162)
21. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
[No Abstract] [Full Text] [Related]
22. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
[No Abstract] [Full Text] [Related]
23. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome.
Wagner AD; Andresen J; Jendro MC; Hülsemann JL; Zeidler H
Arthritis Rheum; 2002 Jul; 46(7):1965-8. PubMed ID: 12124882
[No Abstract] [Full Text] [Related]
24. Can tumor necrosis factor alpha blockade predispose to severe babesiosis?
Taiwo B; Lee C; Venkat D; Tambar S; Sutton SH
Arthritis Rheum; 2007 Feb; 57(1):179-81. PubMed ID: 17266091
[No Abstract] [Full Text] [Related]
25. Maintaining and optimising anti-TNF therapy.
Somerville M
Musculoskeletal Care; 2007 Dec; 5 Suppl 1():1-17. PubMed ID: 18050263
[No Abstract] [Full Text] [Related]
26. [Are there differences among anti-TNFα biological drugs?].
Valesini G
Reumatismo; 2005; 57(4 Suppl):1-2. PubMed ID: 16385348
[TBL] [Abstract][Full Text] [Related]
27. TNF- alpha inhibitors.
Jackson JM
Dermatol Ther; 2007; 20(4):251-64. PubMed ID: 17970890
[TBL] [Abstract][Full Text] [Related]
28. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target.
Boettger MK; Hensellek S; Richter F; Gajda M; Stöckigt R; von Banchet GS; Bräuer R; Schaible HG
Arthritis Rheum; 2008 Aug; 58(8):2368-78. PubMed ID: 18668541
[TBL] [Abstract][Full Text] [Related]
29. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
30. [Biological treatment of rare inflammatory rheumatic diseases].
Baslund B
Ugeskr Laeger; 2008 Jun; 170(24):2150-2. PubMed ID: 18565301
[TBL] [Abstract][Full Text] [Related]
31. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
[No Abstract] [Full Text] [Related]
32. [Anti-TNF-alpha therapy for heart failure: etanercept, infliximab].
Matsumori A
Nihon Rinsho; 2007 May; 65 Suppl 5():176-81. PubMed ID: 17569314
[No Abstract] [Full Text] [Related]
33. Anti-tumour necrosis factor agents and lipid profile: a class effect?
Garcês SP; Parreira Santos MJ; Vinagre FM; Roque RM; da Silva JA
Ann Rheum Dis; 2008 Jun; 67(6):895-6. PubMed ID: 18474660
[No Abstract] [Full Text] [Related]
34. Psoriasis induced by anti-tumor necrosis factor therapy: a class effect?
Richette P; Viguier M; Bachelez H; Bardin T
J Rheumatol; 2007 Feb; 34(2):438-9. PubMed ID: 17304662
[No Abstract] [Full Text] [Related]
35. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship.
Carter JD; Valeriano J; Vasey FB
J Rheumatol; 2006 May; 33(5):1014-7. PubMed ID: 16652431
[TBL] [Abstract][Full Text] [Related]
36. Pulsating back pain associated with tumor necrosis factor-alpha blockade.
Rozin AP; Braun-Moscovici Y; Balbir-Gurman A
Ann Pharmacother; 2008 Dec; 42(12):1912-3. PubMed ID: 19033477
[No Abstract] [Full Text] [Related]
37. Drug-induced systemic lupus erythematosus associated with etanercept therapy.
Shakoor N; Michalska M; Harris CA; Block JA
Lancet; 2002 Feb; 359(9306):579-80. PubMed ID: 11867114
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor inhibitors in the treatment of chronic inflammatory diseases. A review of immunogenicity and potential implications.
Flood J
Manag Care; 2009 Apr; 18(4 Suppl 3):1-5. PubMed ID: 19562866
[No Abstract] [Full Text] [Related]
39. Comment on prescribing tumor necrosis factor inhibitors.
Hanauer LB
Arthritis Rheum; 2002 Jun; 47(3):347-8. PubMed ID: 12115169
[No Abstract] [Full Text] [Related]
40. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus.
Mikhail M; Weinberg JM; Smith BL
Arch Dermatol; 2008 Apr; 144(4):453-6. PubMed ID: 18427038
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
